Rad51 Antibody (14B4)

Western Blot: Rad51 Antibody (14B4) [NB100-148]

Western Blot: Rad51 Antibody (14B4) [NB100-148] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Rad51 antibody [14B4] diluted at 1:500. The HRP-conjugated anti-mouset IgG antibody (NBP2-19382) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

Western Blot: Rad51 Antibody (14B4) [NB100-148]

Western Blot: Rad51 Antibody (14B4) [NB100-148] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Rad51 antibody [14B4] diluted at 1:500. The HRP-conjugated anti-mouset IgG antibody (NBP2-19382) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

Western Blot: Rad51 Antibody (14B4) [NB100-148]

Western Blot: Rad51 Antibody (14B4) [NB100-148] - Various whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Rad51 antibody [14B4] diluted at 1:500. The HRP-conjugated anti-mouse IgG antibody (NBP2-19382) was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced.

Immunocytochemistry/ Immunofluorescence: Rad51 Antibody (14B4) [NB100-148]

Immunocytochemistry/Immunofluorescence: Rad51 Antibody (14B4) [NB100-148] - Staining of RAD51 nuclear foci in U2OS cells using RAD51 14B4 antibody. Cells were pre-extracted with CSK buffer before fixation with 4% PFA. RAD51 14B4 was used at 1:1000 dultion. DAPI was used to counterstain the nucleus. Scale bar, 10 mciro-meter.

Immunoprecipitation: Rad51 Antibody (14B4) [NB100-148]

Immunoprecipitation: Rad51 Antibody (14B4) [NB100-148] - HeLa whole cell extract prepared with lysis 180 buffer (40 mM Tris-HCl pH8.0, 180 mM NaCl, 1 mMEDTA, 0.5% NP-40). Rabbit anti-RAD51 antibody was used for subsequent WB detection of immunoprecipated RAD51.

Knockdown Validated: Rad51 Antibody (14B4) [NB100-148]

Knockdown Validated: Rad51 Antibody (14B4) [NB100-148] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with Rad51 antibody [14B4].

Western Blot: Rad51 Antibody (14B4) [NB100-148] -

Western Blot: Rad51 Antibody (14B4) [NB100-148] - YFP-PALB2 & YFP-PALB2 146AAAA binds RAD51 equally.Lysates from HEK293T cells expressing the indicated constructs were subjected to GFP-Trap pulldown & immunoblotting against YFP or RAD51. YFP alone was used as a negative control. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/31017574), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: Rad51 Antibody (14B4) [NB100-148] -

Immunocytochemistry/ Immunofluorescence: Rad51 Antibody (14B4) [NB100-148] - Bractoppin Selectively Interrupts BRCA1-Dependent Steps in DNA Repair by Homologous Recombination(A) Confocal images depicting at high magnification the recruitment of the RPA32 protein into nuclear foci after the indicated treatments. Experiments were carried out as described as in Figure 5A. Staining in the upper row is for RPA32 (green), middle row, for mCherry-BRCA1 tBRCT (red); lower row, merged red & green staining, with DNA staining (DAPI) in blue. Scale bar represents 10 μm.(B) Recruitment of RAD51 protein into nuclear foci, measured & depicted as described in (A). Scale bar represents 10 μm.(C) Percentage of cells positive for radiation-induced nuclear RPA32 foci (mean ± SD; n = 5,300, 0 Gy; 3,200, 16 Gy; 3,600, BRCA1 tBRCT; 3,400, Bractoppin; 3,500, CCBT2047) enumerated by high-content imaging (see the STAR Methods). Statistical significance was performed using an unpaired two-tailed t test. ***p ≤ 0.001. Similar results were observed in three independent repeats.(D) Percentage of cells containing nuclear RAD51 foci enumerated & depicted as described in (B). ***p ≤ 0.001. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29606576), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: Rad51 Antibody (14B4) [NB100-148] -

Western Blot: Rad51 Antibody (14B4) [NB100-148] - MiCas9’s beneficial effects are Brex27 & RAD51 dependent.a Indel rates by spCas9, miCas9, & miCas9-mutant at the on-target site for sg-AAVS1 & the off-target site 1 for sg-EMX1. b Indel rates estimated by T7E1 assay by spCas9 & miCas9 with or without the use of RAD51 inhibitor, B02. c Co-IP results by using anti-flag (left) or anti-RAD51 (right) antibodies followed western blot for RAD51 or Cas9. d ChIP assay results with anti-RAD51 antibody at the proximal region of the sg-AAVS1 target locus. Sp: spCas9, Mi: miCas9, Mi-mut: miCas9-mutant. #Reads: Average amplicon reads per sample. Three independent experiments were performed for each condition. Data are presented as mean ± standard error of means (SEM). Unpaired t-test (two tailed) was used to compare data using GraphPad Prism 8 software (GraphPad Software, Inc., San Diego, CA). Source data are available in the Source Data file. Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33247137), licensed under a CC-BY license. Not internally tested by Novus Biologicals.